Social media

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our ...

ICON’s Patient Centred Outcomes team advanced key research in 2025, with over 45 highly experienced specialists supporting programmes across major therapy areas. With twelve peer‑reviewed papers, two educational events...

ICON’s Patient Centred Outcomes team advanced key research in 2025, with over 45 highly experienced specialists supporting programmes across major therapy areas. With twelve peer‑reviewed papers, two educational events...

During World Parkinson’s Awareness Month, we recognise the urgency of advancing research that can improve outcomes for people living with Parkinson’s disease. ICON has supported numerous neurodegeneration programmes, he...

ICON is pleased to participate in the upcoming PharmaSUG India Single Day Event, taking place on 11 April at the Eli Lilly office in Bangalore. Madhan Kumar, Statistical Programmer II, will deliver a presentation titled...

ICON is pleased to participate in the upcoming PharmaSUG India Single Day Event, taking place on 11 April at the Eli Lilly office in Bangalore. Madhan Kumar N., Statistical Programmer II, will deliver a presentation tit...

Robust NMA depends on systematic feasibility assessment, careful network construction and rigorous model evaluation. The paper details the workflow from literature review to treatment ranking, highlighting the importan...

Attending World Vaccine Congress? Stop by booth \#222 to meet the ICON team to learn how our experience across 180+ vaccine studies, end‑to‑end product development expertise, and fully integrated vaccine‑development solu...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth \#31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small mole...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth #31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small molec...

2026 marks the first real entry of high risk medical devices into EU JCAs. From implantable prosthetics to active implantable devices, 15 categories have been identified as early candidates. This shift represents a maj...

2026 marks the first real entry of high risk medical devices into EU JCAs. From implantable prosthetics to active implantable devices, 15 categories have been identified as early candidates. This shift represents a maj...